Organon & Co (OGN)
20.73
-0.02
(-0.10%)
USD |
NYSE |
Jun 10, 15:32
Organon Cash from Investing (TTM): -302.00M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -302.00M |
December 31, 2023 | -260.00M |
September 30, 2023 | -240.00M |
June 30, 2023 | -398.00M |
March 31, 2023 | -411.00M |
December 31, 2022 | -420.00M |
September 30, 2022 | -848.00M |
Date | Value |
---|---|
June 30, 2022 | -696.00M |
March 31, 2022 | -862.00M |
December 31, 2021 | -837.00M |
September 30, 2021 | -466.00M |
June 30, 2021 | -455.00M |
March 31, 2021 | -247.00M |
December 31, 2020 | -258.00M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-862.00M
Minimum
Mar 2022
-240.00M
Maximum
Sep 2023
-478.57M
Average
-415.50M
Median
Cash from Investing (TTM) Benchmarks
Amgen Inc | -27.78B |
Pfizer Inc | -33.86B |
Pacira BioSciences Inc | -4.172M |
Amphastar Pharmaceuticals Inc | -627.55M |
Moderna Inc | 2.313B |